Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia

References

• NelsonMHPaulosCMNovel immunotherapies for hematologic malignanciesImmunol Rev201526319010525510273
   PubMed Web of Science ®Google Scholar
• WeilandJElderAForsterVHeidenreichOKoschmiederSVormoorJCD19: a multifunctional immunological target molecule and its implications for B lineage acute lymphoblastic leukemiaPediatr Blood Cancer20156271144114825755168
   PubMed Web of Science ®Google Scholar
• MaudeSLFreyNShawPAChimeric antigen receptor T cells for sustained remissions in leukemiaN Engl J Med2014371161507151725317870
   PubMed Web of Science ®Google Scholar
• LeeDWKochenderferJNStetler-StevensonMT cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialLancet2015385996751752825319501
   PubMed Web of Science ®Google Scholar
• ZimmermanZManiarTNagorsenDUnleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapyInt Immunol2015271313725239133
   PubMed Web of Science ®Google Scholar
• ThomasXBlinatumomab: a new era of treatment for adult ALL?Lancet Oncol20151616725524799
   PubMed Web of Science ®Google Scholar
• BassanRToward victory in adult ALL: blinatumomab joins inBlood2012120265094509523258898
   PubMed Web of Science ®Google Scholar
• NagorsenDBaeuerlePAImmunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomabExp Cell Res201131791255126021419116
   PubMed Web of Science ®Google Scholar
• BargouRLeoEZugmaierGTumor regression in cancer patients by very low doses of a T cell-engaging antibodyScience2008321589197497718703743
   PubMed Web of Science ®Google Scholar
• HoffmannPHofmeisterRBrischweinKSerial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody constructInt J Cancer200511519810415688411
   PubMed Web of Science ®Google Scholar
• RaponiSDe ProprisMSIntoppaSFlow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeuk Lymphoma20115261098110721348573
   PubMed Web of Science ®Google Scholar
• KlingerMBrandlCZugmaierGImmunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabBlood2012119266226623322592608
   PubMed Web of Science ®Google Scholar
• BaeuerlePAReinhardtCBispecific T-cell engaging antibodies for cancer therapyCancer Res200969124941494419509221
   PubMed Web of Science ®Google Scholar
• PortellCAWenzellCMAdvaniASClinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemiaClin Pharmacol20135suppl 151123671399
   PubMedGoogle Scholar
• RathiCMeibohmBClinical pharmacology of bispecific antibody constructsJ Clin Pharmacol201555suppl 3S21S2825707960
   PubMed Web of Science ®Google Scholar
• RuellaMGillSHow to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemiaExpert Opin Biol Ther201515676176625640460
   PubMed Web of Science ®Google Scholar
• WuBHijaziYWolfAPharmacokinetics (PK) of blinatumomab and its clinical implicationsJ Clin Oncol201331sul abstr3048
   Google Scholar
• von StackelbergALocatelliFZugmaierGPhase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatmentBlood2014124 abstr2292
   Web of Science ®Google Scholar
• SchubANägeleVZugmaierGImmunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)J Clin Oncol201331sul abstr7020
   Google Scholar
• ZugmaierGToppMSAlekarSLong-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemiaBlood Cancer J2014424425192414
   PubMed Web of Science ®Google Scholar
• DuellJDittrichMBedkeTCrucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patientsBlood2014124abstr2291
   Web of Science ®Google Scholar
• ToppMSKuferPGökbugetNTargeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalJ Clin Oncol201129182493249821576633
   PubMed Web of Science ®Google Scholar
• ToppMSGökbugetNZugmaierGLong-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLBlood2012120265185518723024237
   PubMed Web of Science ®Google Scholar
• ToppMSGökbugetNZugmaierGPhase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaJ Clin Oncol201432364134414025385737
   PubMed Web of Science ®Google Scholar
• ToppMSGökbugetNSteinASSafety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyLancet Oncol2015161576625524800
   PubMed Web of Science ®Google Scholar
• GoekbugetNDombretHBonifacioMBLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL)Blood2014124abstr379
   Web of Science ®Google Scholar
• GoreLLocatelliFZugmaierGInitial results from a phase 2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemiaBlood2014124abstr3703
   Web of Science ®Google Scholar
• BarrettDMTeacheyDTGruppSAToxicity management for patients receiving novel T-cell engaging therapiesCurr Opin Pediatr2014261434924362408
   PubMed Web of Science ®Google Scholar
• TeacheyDTRheingoldSRMaudeSLCytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyBlood2013121265154515723678006
   PubMed Web of Science ®Google Scholar
• JanMMajetiRClonal evolution of acute leukemia genomesOncogene201332213514022349821
   PubMed Web of Science ®Google Scholar
• MaXEdmonsonMYergeauDRise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemiaNat Commun20156660425790293
   PubMed Web of Science ®Google Scholar
• AiJAdvaniACurrent status of antibody therapy in ALLBr J Haematol2015168447148025382151
   PubMed Web of Science ®Google Scholar